These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 36929345)

  • 1. Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.
    Tahami Monfared AA; Ye W; Sardesai A; Folse H; Chavan A; Kang K; Zhang Q
    Neurol Ther; 2023 Jun; 12(3):795-814. PubMed ID: 36929345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting the Societal Value of Lecanemab in Early Alzheimer's Disease in Japan: A Patient-Level Simulation.
    Igarashi A; Azuma MK; Zhang Q; Ye W; Sardesai A; Folse H; Chavan A; Tomita K; Tahami Monfared AA
    Neurol Ther; 2023 Aug; 12(4):1133-1157. PubMed ID: 37188886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Potential Economic Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.
    Tahami Monfared AA; Tafazzoli A; Chavan A; Ye W; Zhang Q
    Neurol Ther; 2022 Sep; 11(3):1285-1307. PubMed ID: 35718854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Path to Improved Alzheimer's Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer's Disease from the CLARITY AD Trial.
    Tahami Monfared AA; Ye W; Sardesai A; Folse H; Chavan A; Aruffo E; Zhang Q
    Neurol Ther; 2023 Jun; 12(3):863-881. PubMed ID: 37009976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.
    Tahami Monfared AA; Tafazzoli A; Ye W; Chavan A; Zhang Q
    Neurol Ther; 2022 Jun; 11(2):863-880. PubMed ID: 35469060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease.
    Herring WL; Gould IG; Fillit H; Lindgren P; Forrestal F; Thompson R; Pemberton-Ross P
    Neurol Ther; 2021 Dec; 10(2):919-940. PubMed ID: 34426940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective.
    Hornberger J; Michalopoulos S; Dai M; Andrade P; Dilla T; Happich M
    J Ment Health Policy Econ; 2015 Jun; 18(2):63-73. PubMed ID: 26231002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
    Pratz KW; Chai X; Xie J; Yin L; Nie X; Montez M; Iantuono E; Downs L; Ma E
    Pharmacoeconomics; 2022 Aug; 40(8):777-790. PubMed ID: 35696071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.
    Bhadhuri A; Dröschel D; Guldimann M; Jetschgo C; Banhazi J; Schwenkglenks M; Sutherland CS
    BMC Health Serv Res; 2022 Jun; 22(1):837. PubMed ID: 35765055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the Cost-effectiveness of a Hypothetical Disease-modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease.
    Boustani M; Doty EG; Garrison LP; Smolen LJ; Belger M; Klein TM; Murphy DR; Burge R; Wall JK; Johnston JA
    Clin Ther; 2022 Nov; 44(11):1449-1462. PubMed ID: 36210219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Cost-effectiveness of Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors.
    Ito K; Chapman R; Pearson SD; Tafazzoli A; Yaffe K; Gurwitz JH
    JAMA Netw Open; 2021 Oct; 4(10):e2129392. PubMed ID: 34677596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus at Increased Cardiovascular Risk in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsapas A; Kourlaba G; Papageorgiou G; Maniadakis N
    Clin Drug Investig; 2018 May; 38(5):417-426. PubMed ID: 29349708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States.
    Ohsfeldt R; Kelton K; Klein T; Belger M; Mc Collam PL; Spiro T; Burge R; Ahuja N
    Clin Ther; 2021 Nov; 43(11):1877-1893.e4. PubMed ID: 34732289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
    Ruiz Vargas E; Sposato LA; Lee SAW; Hachinski V; Cipriano LE
    Stroke; 2018 Dec; 49(12):2844-2850. PubMed ID: 30571418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey.
    Tugay D; Top M; Aydin Ö; Bavbek S; Damadoğlu E; Öner Erkekol F; Koca Kalkan I; Kalyoncu AF; Karakaya G; Oğuzülgen IK; Türktaş H; Abraham I
    J Med Econ; 2023; 26(1):720-730. PubMed ID: 37129881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Chapman RH; Kumar VM; Synnott PG; Agboola F; Campbell JD
    J Manag Care Spec Pharm; 2019 Jan; 25(1):80-87. PubMed ID: 30589626
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.